多囊卵巢综合征/多内分泌代谢卵巢综合征研究资助不足持续存在
该研究查询NIH研究组合在线报告工具,比较2016-2022年PCOS/PMOS与类风湿关节炎、结核病和系统性红斑狼疮的NIH资助。
要点
- PCOS/PMOS资助较2006-2015年增加约50%,但增幅不及RA和SLE。
- PCOS/PMOS资助来自16个NIH研究所/中心,其中NICHD占44.8%。
核心结论
- 2016-2022年NIH对PCOS/PMOS研究的资助较2006-2015年增加约50%,但仍低于RA和SLE的资助总额与增幅。
- 近期倡导工作似乎与NIH资助增加相关,但该高患病率且高疾病负担的女性健康障碍在研究资助上的持续差异仍需解决。
研究设计与样本
- 研究查询了NIH研究组合在线报告工具,比较2016-2022年PCOS/PMOS与RA、TB、SLE的NIH资助情况。
主要发现
- 与2006-2015年相比,PCOS/PMOS、RA、TB和SLE的资助差异分别为48%、577%、-15%和689%。
- 2016-2022年PCOS/PMOS研究获得16个NIH研究所/中心的533项资助,其中44.8%来自NICHD,而前一研究期为68.4%。
- RA、TB和SLE的资助分别来自27、36和27个研究所/中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic Ovary Syndrome (PCOS), renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), is a common endocrine disorder affecting 4-20% of women worldwide. Prior analysis (2006-2015) demonstrated that PCOS/PMOS received disproportionately less U.S. National Institutes of Health (NIH) funding compared with other chronic disorders of similar prevalence and/or morbidity, namely rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE). A number of bipartisan advocacy efforts have been made since. OBJECTIVE: To determine the impact of current advocacy efforts on NIH funding for PCOS/PMOS research. METHODS: NIH Research Portfolio Online Reporting Tools were queried. RESULTS: In 2016-22 mean annual NIH funding for PCOS/PMOS was $31.8 M vs. $262.4 M (RA), $66.1 M (TB), and $420.4 M (SLE), a 48%, 577%, -15% and 689% difference, respectively, compared to 2006-2015. In 2016-2022 PCOS/PMOS research received 533 awards from 16 NIH Institute/Centers (ICs), with 44.8% of funding arising from the National Institute of Child Health and Human Development (NICHD), compared with 68.4% in the prior study period. RA, TB, and SLE funding came from 27, 36, and 27 ICs, respectively. CONCLUSIONS: In 2016-2022 PCOS/PMOS research funding by the NIH increased by ∼50% compared to 2006-2015, albeit still less than the increase and total funding for RA and SLE. There appeared to be greater interest in PCOS/PMOS by a higher number of ICs. Recent advocacy efforts appear to be associated with increasing NIH funding. However, much remains to be done to address persistent disparities in research funding for this highly prevalent and morbid women's health disorder.
引用
- Tilton AN, Ottey S, Patterson W, et al. Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) Research Underfunding Continues. J Clin Endocrinol Metab. 2026. PMID: 42427099. doi:10.1210/clinem/dgag272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。